公开(公告)号：EP0759757A1

公开(公告)日：1997-03-05

申请号：EP95924570.0

申请日：1995-05-12

申请人： MERCK & CO., INC.

发明人： BRENNER, Gerald, S. ,  KATDARE, Ashok, V. ,  PRETZER, Denise ,  WHITEFORD, Donna, T.

IPC分类号： A61K9 ,  A61K31 ,  A61K47 ,  A61P19 ,  A61P29 ,  A61P35 ,  A61P43

CPC分类号： A61K9/0095 ,  A61K31/663

摘要： Disclosed is a therapy protocol for treating and for preventing bone loss in patients who have difficulty in swallowing by administering a liquid formulation of alendronate which can be easily swallowed. Also described are pharmaceutical dosage forms of a syrup, aqueous solution, a solution formed from a reconstituted powder, of alendronate, for carrying out the therapeutic method.

公开(公告)号：EP0939624B1

公开(公告)日：2003-12-17

申请号：EP97924695.6

申请日：1997-05-13

申请人： MERCK & CO., INC.

发明人： KATDARE, Ashok, V. ,  KRAMER, Kenneth, A. ,  GARDNER, Colin, R.

IPC分类号： A61K9/46 ,  A61K31/66

CPC分类号： A61K31/675 ,  A61K9/0007 ,  A61K31/663

摘要： An effervescent formulation of alendronate contains an acid source, a carbonate source, a binder, a lubricant and, optionally, flavoring agents, colorants and sweeteners.

公开(公告)号：EP0759757B1

公开(公告)日：2002-08-21

申请号：EP95924570.5

申请日：1995-05-12

申请人： MERCK & CO., INC.

发明人： BRENNER, Gerald, S. ,  KATDARE, Ashok, V. ,  PRETZER, Denise ,  WHITEFORD, Donna, T.

IPC分类号： A61K31/66 ,  A61K9/00 ,  A61K47/12 ,  A61P19/08

CPC分类号： A61K9/0095 ,  A61K31/663

摘要： Disclosed is a therapy protocol for treating and for preventing bone loss in patients who have difficulty in swallowing by administering a liquid formulation of alendronate which can be easily swallowed. Also described are pharmaceutical dosage forms of a syrup, aqueous solution, a solution formed from a reconstituted powder, of alendronate, for carrying out the therapeutic method.

公开(公告)号：EP0939624A1

公开(公告)日：1999-09-08

申请号：EP97924695.0

申请日：1997-05-13

申请人： MERCK & CO., INC.

发明人： KATDARE, Ashok, V. ,  KRAMER, Kenneth, A. ,  GARDNER, Colin, R.

IPC分类号： A61K9 ,  A61K31 ,  A61K47

CPC分类号： A61K31/675 ,  A61K9/0007 ,  A61K31/663

摘要： An effervescent formulation of alendronate contains an acid source, a carbonate source, a binder, a lubricant and, optionally, flavoring agents, colorants and sweeteners.

公开(公告)号：EP0756484A1

公开(公告)日：1997-02-05

申请号：EP95917120.0

申请日：1995-04-24

申请人： Merck & Co., Inc.

发明人： KATDARE, Ashok, V. ,  KRAMER, Kenneth, A.

IPC分类号： A61K9 ,  A61K31

CPC分类号： A61K31/66 ,  A61K9/2095

摘要： Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by wet granulation tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease. These compositions are prepared without the addition of binder; instead, the drug itself acts as a binder.

公开(公告)号：EP1083901B1

公开(公告)日：2003-04-16

申请号：EP99925793.4

申请日：1999-05-24

申请人： MERCK & CO., INC.

发明人： BATRA, Udit ,  HIGGINS, Raymond, J. ,  THOMPSON, Karen, C. ,  KATDARE, Ashok, V.

IPC分类号： A61K31/535 ,  A61K9/20

CPC分类号： A61K31/535 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2866

摘要： This invention relates to a 50 % drug loaded compressed tablet formulation for efavirenz. Efavirenz is a non-nucleoside reverse trancriptase inhibitor being studied clinically for use in the treatment of HIV infections and AIDS.

摘要翻译： 本发明涉及用于依法韦仑的50％载药压缩片剂。 依法韦仑是临床研究用于治疗HIV感染和艾滋病的非核苷逆转录酶抑制剂。

公开(公告)号：EP0756484B1

公开(公告)日：2002-10-09

申请号：EP95917120.8

申请日：1995-04-24

申请人： Merck & Co., Inc.

发明人： KATDARE, Ashok, V. ,  KRAMER, Kenneth, A.

IPC分类号： A61K31/66 ,  A61K9/20

CPC分类号： A61K31/66 ,  A61K9/2095

摘要： Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by wet granulation tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease. These compositions are prepared without the addition of binder; instead, the drug itself acts as a binder.

公开(公告)号：EP1196175A1

公开(公告)日：2002-04-17

申请号：EP00946859.6

申请日：2000-06-27

申请人： Merck & Co., Inc.

发明人： CHEN, Tzyy-Show, H. ,  KATDARE, Ashok, V. ,  NYAIRO, Thomas, G.

IPC分类号： A61K31/663 ,  A61K9/20 ,  A61P19/10

CPC分类号： A61K9/2018 ,  A61K31/663

摘要： The present invention relates to novel pharmaceutical tablets useful for administering pharmaceutical active ingredients, such as bisphosphonates. These tablets have improved surface properties which can aid esophageal transit, thereby reducing the potential for adverse gesture intestinal effects. The present invention also relates to processes for making said novel pharmaceutical tablets.

公开(公告)号：EP1083901A1

公开(公告)日：2001-03-21

申请号：EP99925793.4

申请日：1999-05-24

申请人： MERCK & CO., INC.

发明人： BATRA, Udit ,  HIGGINS, Raymond, J. ,  THOMPSON, Karen, C. ,  KATDARE, Ashok, V.

IPC分类号： A61K31/535 ,  A61K9/20

CPC分类号： A61K31/535 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2866

摘要： This invention relates to a 50 % drug loaded compressed tablet formulation for efavirenz. Efavirenz is a non-nucleoside reverse trancriptase inhibitor being studied clinically for use in the treatment of HIV infections and AIDS.